bioRxiv preprint doi: https://doi.org/10.1101/2021.03.12.435190; this version posted August 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Platelet transcriptome yields progressive markers in chronic 2 myeloproliferative neoplasms and identifies putative targets of therapy 3 4 Zhu Shen1, Wenfei Du1, Cecelia Perkins2, Lenn Fechter2, Vanita Natu3, Holden Maecker4, Jesse Rowley5, 5 Jason Gotlib2,6,8, James Zehnder2,6,7,8, and Anandi Krishnan2,7* 6 7 Affiliations 8 1Department of Statistics, Stanford University, Stanford, CA 9 2Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 10 3Stanford Functional Genomics Facility, Stanford University School of Medicine, Stanford, CA 11 4Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 12 5Department of Internal Medicine, University of Utah, Salt Lake City, UT 13 6Department of Medicine, Stanford University School of Medicine, Stanford, CA 14 7Department of Pathology, Stanford University, Stanford, CA 15 8These authors contributed equally 16 17 *Corresponding Author: 18 Anandi Krishnan, PhD 19 Stanford University, Stanford, CA 20
[email protected] 21 22 23 24 25 Highlights 26 Leveraging two independent and mutually validating MPN patient cohorts, we identify progressive 27 transcriptomic markers that also enable externally validated prediction in MPNs. 28 29 Our platelet RNA-Seq data identifies impaired protein homeostasis as prominent in MPN progression and 30 offers putative targets of therapy.